Selected article for: "protein domain and vaccine development"
Author: Zha, Lisha; Chang, Xinyue; Zhao, Hongxin; Mohsen, Mona O.; Hong, Liang; Zhou, Yuhang; Chen, Hongquan; Liu, Xuelan; Zhang, Jie; Li, Dong; Wu, Ke; Martina, Byron; Wang, Junfeng; Vogel, Monique; Bachmann, Martin F.
Title: Development of a Vaccine against SARS-CoV-2 Based on the Receptor-Binding Domain Displayed on Virus-Like Particles
  • Cord-id: j9uq7m9j
  • Document date: 2021_4_16
    • ID: j9uq7m9j
    Snippet: The ongoing coronavirus disease (COVID-19) pandemic is caused by a new coronavirus (severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)) first reported in Wuhan City, China. From there, it has been rapidly spreading to many cities inside and outside China. Nowadays, more than 110 million cases with deaths surpassing 2 million have been recorded worldwide, thus representing a major health and economic issues. Rapid development of a protective vaccine against COVID-19 is therefore of
    Document: The ongoing coronavirus disease (COVID-19) pandemic is caused by a new coronavirus (severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)) first reported in Wuhan City, China. From there, it has been rapidly spreading to many cities inside and outside China. Nowadays, more than 110 million cases with deaths surpassing 2 million have been recorded worldwide, thus representing a major health and economic issues. Rapid development of a protective vaccine against COVID-19 is therefore of paramount importance. Here, we demonstrated that the recombinantly expressed receptor-binding domain (RBD) of the spike protein can be coupled to immunologically optimized virus-like particles derived from cucumber mosaic virus (CuMV(TT)). The RBD displayed CuMV(TT) bound to ACE2, the viral receptor, demonstrating proper folding of RBD. Furthermore, a highly repetitive display of the RBD on CuMV(TT) resulted in a vaccine candidate that induced high levels of specific antibodies in mice, which were able to block binding of the spike protein to ACE2 and potently neutralize SARS-CoV-2 virus in vitro.

    Search related documents:
    Co phrase search for related documents
    • acute respiratory syndrome and long distance: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • acute respiratory syndrome and long last antibody: 1
    • acute respiratory syndrome and low temperature: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and luciferase activity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • acute respiratory syndrome and luciferase assay system: 1
    • acute respiratory syndrome and luminescence detection: 1, 2
    • acute respiratory syndrome and lung symptom: 1, 2, 3, 4, 5, 6, 7, 8
    • acute respiratory syndrome coronavirus and adjuvant potent: 1, 2
    • acute respiratory syndrome coronavirus and long distance: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute respiratory syndrome coronavirus and long last antibody: 1
    • acute respiratory syndrome coronavirus and low temperature: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • acute respiratory syndrome coronavirus and luciferase activity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acute respiratory syndrome coronavirus and luciferase assay system: 1
    • acute respiratory syndrome coronavirus and luminescence detection: 1, 2
    • acute respiratory syndrome coronavirus and lung symptom: 1, 2, 3
    • acute respiratory syndrome coronavirus type and low temperature: 1
    • acute respiratory syndrome coronavirus type and luciferase activity: 1
    • acute respiratory syndrome coronavirus type and lung symptom: 1
    • long distance and low temperature: 1